ORGANIZATION

• Member Companies Conducted 682 Clinical Trials in Japan in 2013: PhRMA/EFPIA
  June 11, 2014

• Generic Versions of Combination Drug Exforge to Be Named “Amvalo”: JSGM
  June 10, 2014

• Santen President Officially Becomes New OPMA Head
  May 29, 2014

• FPMAJ, JPMA Issue Joint Statement Opposing Once-Yearly NHI Price Revision
  May 29, 2014

• JPWA Chief Highlights Progress in Single-Product, Single-Price Trading
  May 27, 2014

• MTPC, MSD Return to JPMA’s BOD
  May 26, 2014

• Yearly NHI Price Revision Not Consistent with Growth Strategy: JPMA Exec
  May 23, 2014

• Astellas Chair Nogimori Sworn in as Head of FPMAJ
  May 22, 2014

• Dainippon Pres. Tada Elected New Chief of JPMA
  May 22, 2014

• Market Share of Generic Drugs Based on New Calculation Method Rose to 44.9% in 3rd Quarter of FY2013: JGA
  May 19, 2014

• Quality Control Essential for Preventing Disruptions in Supplies of Generic Drugs; Double-Sourcing Not Enough
  May 7, 2014

• Medwatcher Calls for Making Physician Payment Disclosure Obligatory by Law
  May 2, 2014

• JPMA Issues New Notification on Promotional Rules Related to Data Presented at Scientific Conferences, Lecture Meetings
  May 1, 2014

• Adoption of CDISC Standards Will Be Daunting Task: JPMA Regulatory Affairs Head
  April 28, 2014

• JPMA Announces New Guidelines on Support for Clinical Research
  April 24, 2014

• Japan Should Stick to Current Mixed Care Scheme: Kenporen Exec Shirakawa
  April 22, 2014

• JMA Pres. Yokokura Voices Opposition to Proposed Mixed Care System, Annual Drug Price Revisions
  April 21, 2014

• Membership Suspension Appropriate for Novartis Pharma Involvement in SIGN Trial: JPMA
  April 21, 2014

• Dainippon’s Takada to Head JPMA Public Affairs Committee
  April 18, 2014

• EFPIA Poised to Present Plan for Japan-Version IMI by Year-End
  April 16, 2014

ページ

• « 先頭
• ‹ Prev
• …
• 59
• 60
• 61
• 62
• 63
• 64
• 65
• 66
• 67
• …
• Next ›
• 最終 »